Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Clinical outcome of non–hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome Michel De Vos,

Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis George Griesinger, M.D.,

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Developmental capacity of in vitro–matured human oocytes retrieved from polycystic ovary syndrome ovaries containing no follicles larger than 6 mm Luis.

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study Arianna D'Angelo, M.D., Rachel.

Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis Ioannis P. Kosmas, M.D.,

No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH George Griesinger, Daniel B. Shapiro, Efstratios.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

A differential cytokine expression profile is induced by highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone in.

Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women Ioannis E. Messinis, M.D., Ph.D.,

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency Carrie.

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Robert F. Casper, M.D. Fertility and Sterility

Conversion of high-response gonadotropin intrauterine insemination cycles to in vitro fertilization results in excellent ongoing pregnancy rates Amy.

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis Dimitra Kyrou,

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized.

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Fertility and Sterility

Effectiveness of highly purified human menopausal gonadotropin vs

Are endometrial parameters by three-dimensional ultrasound and power Doppler angiography related to in vitro fertilization/embryo transfer outcome? Luis.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone–releasing hormone antagonist.

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.

In vitro sildenafil citrate use as a sperm motility stimulant

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.

Increased pregnancy rates after ultralong postoperative therapy with gonadotropin- releasing hormone analogs in patients with endometriosis Dagmar Rickes,

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome Ernesto Bosch,

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome Kris Poppe, M.D., Ph.D., David Unuane,

Ernesto Bosch, M. D. , Elena Labarta, M. D

Presentation transcript:

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas Zikopoulos, M.D., Ph.D., Johan Smitz, M.D., Ph.D., Michel Camus, M.D., Herman Tournaye, M.D., Ph.D., Andre C Van Steirteghem, M.D., Ph.D., Paul Devroey, M.D., Ph.D. Fertility and Sterility Volume 82, Issue 1, Pages 223-226 (July 2004) DOI: 10.1016/j.fertnstert.2003.12.027

FIGURE 1 Serum LH, FSH, E2, and P levels on days 1, 3, 6, 8, and 9 of stimulation with rec-FSH and GnRH antagonists. The 95% confidence interval is also shown. Kolibianakis. Initiation of GnRH antagonist on day 1 in IVF. Fertil Steril 2004. Fertility and Sterility 2004 82, 223-226DOI: (10.1016/j.fertnstert.2003.12.027)